576 results on '"Kalgutkar, Amit S."'
Search Results
2. Small molecule branched-chain ketoacid dehydrogenase kinase (BDK) inhibitors with opposing effects on BDK protein levels
3. Reactive Electrophiles and Metabolic Activation
4. Development of a sensitive LC-MS/MS assay to support human microdose study for an oral agonist of the GLP-1 receptor
5. A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19
6. A Kinetic Model for Assessing Potential Nitrosamine Carcinogenicity.
7. Bioactivation and reactivity research advances – 2023 year in review.
8. Biotransformation research advances – 2023 year in review.
9. Nicotinic acid transport into human liver involves organic anion transporter 2 (SLC22A7)
10. Is there enough evidence to classify cycloalkyl amine substituents as structural alerts?
11. Structural attributes influencing unbound tissue distribution
12. Mechanisms of Nitrosamine Mutagenicity and Their Relationship to Rodent Carcinogenic Potency
13. Reactive Metabolites
14. Biotransformation research advances – 2022 year in review
15. On-resin N-methylation of cyclic peptides for discovery of orally bioavailable scaffolds
16. Bioactivation and reactivity research advances – 2022 year in review‡
17. Activation of Skeletal Muscle AMPK Promotes Glucose Disposal and Glucose Lowering in Non-human Primates and Mice
18. Managing Reactive Metabolites in Drug Discovery and Development
19. Biochemically Based Design of Cyclooxygenase-2 (COX-2) Inhibitors: Facile Conversion of Nonsteroidal Antiinflammatory Drugs to Potent and Highly Selective COX-2 Inhibitors
20. Mitigating a Bioactivation Liability with an Azetidine-Based Inhibitor of Diacylglycerol Acyltransferase 2 (DGAT2) En Route to the Discovery of the Clinical Candidate Ervogastat
21. The Role of Biotransformation Studies in Reducing Drug Attrition
22. Species differences in plasma protein binding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease inhibitor nirmatrelvir
23. Strategies for Assessing Acceptable Intakes for Novel N-Nitrosamines Derived from Active Pharmaceutical Ingredients
24. Discovery of Ervogastat (PF-06865571): A Potent and Selective Inhibitor of Diacylglycerol Acyltransferase 2 for the Treatment of Non-alcoholic Steatohepatitis
25. Dedication of 35-year Chemical Research in Toxicology Anniversary to Founding Editor Larry Marnett
26. Role of Bioactivation in Idiosyncratic Drug Toxicity: Structure–Toxicity Relationships
27. Drug-Induced Liver Injury (DILI) Arising from Inhibition of Bile Acid Transport Proteins
28. Aspirin-like Molecules that Covalently Inactivate Cyclooxygenase-2
29. Novel advances in biotransformation and bioactivation research – 2020 year in review
30. Biotransformation novel advances – 2021 year in review
31. Transporter-Enzyme Interplay in the Pharmacokinetics of PF-06835919, a First-In-Class Ketohexokinase Inhibitor for Metabolic Disorders and Nonalcoholic Fatty Liver Disease
32. Structural diversity of selective COX-2 inhibitors
33. Discovery of a New Class of Selective Cyclooxygenase-2 (COX-2) Inhibitor that Covalently Modifies the Isozyme
34. Metabolism and Excretion of Nirmatrelvir in Humans Using Quantitative Fluorine Nuclear Magnetic Resonance Spectroscopy: A Novel Approach for Accelerating Drug Development
35. A Small-Molecule Oral Agonist of the Human Glucagon-like Peptide-1 Receptor
36. Comprehensive Nonclinical Safety Assessment of Nirmatrelvir Supporting Timely Development of the SARS-COV-2 Antiviral Therapeutic, Paxlovid™
37. IN VITROMETHODS FOR EVALUATION OF DRUG METABOLISM
38. DEALING WITH REALITY
39. sj-pdf-2-ijt-10.1177_10915818221095489 – Supplemental Material for Comprehensive Nonclinical Safety Assessment of Nirmatrelvir Supporting Timely Development of the SARS-COV-2 Antiviral Therapeutic, Paxlovid™
40. Inactivation of Prostaglandin Endoperoxide Synthase (PGHS) by N-(Substituted)Maleimides
41. Handling reactive metabolite positives in drug discovery: What has retrospective structure–toxicity analyses taught us?
42. Pharmacokinetics, mass balance, metabolism, and excretion of the liver-targeted acetyl-CoA carboxylase inhibitor PF-05221304 (clesacostat) in humans
43. Practical and Science-Based Strategy for Establishing Acceptable Intakes for Drug Product N-Nitrosamine Impurities
44. Disposition of Nirmatrelvir, an Orally Bioavailable Inhibitor of SARS-CoV-2 3C-Like Protease, across Animals and Humans
45. Chemical Research in Toxicology at 35: Recognizing the Impact of Professor Larry Marnett
46. An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19
47. Future of Biotransformation Science in the Pharmaceutical Industry
48. N-(3,4-dimethoxyphenethyl)-4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)-6,7-dimethoxyquinazolin-2-amine (CP-100,356) as a “chemical knock-out equivalent” to assess the impact of efflux transporters on oral drug absorption in the rat
49. An Oral SARS-CoV-2 Mpro Inhibitor Clinical Candidate for the Treatment of COVID-19
50. Novel advances in biotransformation and bioactivation research–2020 year in review
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.